From: Factors related to outcome of bloodstream infections due to Candida parapsilosis complex
Variables | Patients with BSIs due to: | ||
---|---|---|---|
C. parapsilosis (n = 63) | C. albicans (n = 146) | P valuea | |
Age (years), median (IQR)b | 67 (43–76) | 51 (66–77) | 0.133 |
Neonates (<3 months) | 1 (2) | 5 (3) | 0.465 |
Elderly (>65 years) | 32 (51) | 72 (49) | 0.844 |
Male sex, n (%) | 35 (56) | 91 (63) | 0.358 |
Ward | |||
Internal Medicine, n (%) | 25 (40) | 52 (36) | 0.448 |
Surgery, n (%) | 17 (27) | 32 (22) | |
Intensive Care Unit, n (%) | 21 (33) | 62 (43) | |
Comorbidities, n (%) | 57 (90) | 137 (94) | 0.387 |
Chronic pulmonary diseases, n (%)c | 9 (14) | 11 (8) | 0.127 |
Haematological malignancy, n (%) | 1 (2) | 8 (5) | 0.203 |
Cardiovascular diseases, n (%)d | 27 (43) | 67 (46) | 0.685 |
Neurological diseases, n (%)e | 10 (16) | 24 (16) | 0.919 |
Gastrointestinal diseases, n (%)f | 21 (33) | 43 (29) | 0.576 |
Diabetes mellitus, n (%) | 8 (13) | 28 (19) | 0.254 |
Solid tumors, n (%) | 15 (24) | 43 (30) | 0.403 |
Chronic renal failure, n (%) | 7 (11) | 12 (8) | 0.504 |
Previous surgery (<30 days), n (%) | 32 (51) | 67 (46) | 0.514 |
Gastrointestinal surgery, n (%) | 8 (13) | 19 (13) | 0.950 |
Cardiovascular surgery, n (%) | 13 (21) | 28 (19) | 0.807 |
Other surgery, n (%) g | 12 (19) | 24 (16) | 0.646 |
Central venous catheter, n (%) | 56 (89) | 127 (87) | 0.702 |
BSI CVC-related, n (%) | 36 (64) | 57 (45) | 0.015 |
Other devices, n (%)h | 57 (90) | 129 (88) | 0.653 |
Previous invasive procedures (<72 h), n (%)i | 16 (25) | 44 (30) | 0.486 |
Parenteral nutrition, n (%) | 43 (68) | 105 (72) | 0.592 |
Immunosuppressive therapy, n (%)j | 18 (29) | 56 (34) | 0.174 |
Neutropenia, n (%) | 4 (6) | 7 (5) | 0.644 |
Septic shock, n (%) | 2 (3) | 12 (8) | 0.180 |
Prior antibiotic therapy, n (%) | 58 (92) | 139 (95) | 0.370 |
Previous antifungal therapy (<30 days), n (%) | 5 (8) | 21 (14) | 0.195 |
Concomitant bacteriemia, n (%) | 15 (24) | 40 (27) | 0.588 |
Other coinfections, n (%)k | 39 (62) | 89 (61) | 0.897 |
Appropriate antifungal therapy, n (%)l | 38 (60) | 92 (63) | 0.712 |
Primary azole therapy | 41 (65) | 77 (53) | 0.098 |
Primary echinocandin therapy | 7 (11) | 34 (23) | 0.041 |
Primary polyene therapy | 1 (2) | 3 (2) | 0.820 |
None | 14 (22) | 32 (22) | 0.961 |
Overall mortality, n (%) | 17 (27) | 61 (42) | 0.042 |
Early mortality (days 1–7), n (%) | 4 (6) | 24 (17) | 0.049 |
Late mortality (days 8–30), n (%) | 13 (21) | 37 (25) | 0.464 |